Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | MAP2K1 S218D |
Gene Variant Detail | |
Relevant Treatment Approaches | MEK inhibitor (Pan) MEK1 Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E MAP2K1 S218D MAP2K1 S222D | melanoma | resistant | Dabrafenib | Preclinical - Cell culture | Actionable | In a preclinical study, expression of MAP2K1 S218D and S222D in melanoma cells harboring BRAF V600E conferred resistance to Tafinlar (dabrafenib) treatment in culture (PMID: 31925410). | 31925410 |
CTNNB1 mut MAP2K1 S218D MAP2K1 S222D | hepatocellular carcinoma | predicted - resistant | WNTinib | Preclinical - Cell culture | Actionable | In a preclinical study, a hepatocellular carcinoma cell line harboring a deletion of CTNNB1 exons and expressing MAP2K1 S218D and S222D was resistant to WNTinib in culture (PMID: 37537299). | 37537299 |